Home » Stocks » PSTV

Plus Therapeutics, Inc. (PSTV)

Stock Price: $2.82 USD -0.27 (-8.87%)
Updated Jan 26, 2021 3:02 PM EST - Market open
Market Cap 14.77M
Revenue (ttm) 1.49M
Net Income (ttm) -4.32M
Shares Out 4.40M
EPS (ttm) -30.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $2.82
Previous Close $3.09
Change ($) -0.27
Change (%) -8.87%
Day's Open 3.16
Day's Range 2.60 - 3.25
Day's Volume 1,320,476
52-Week Range 1.05 - 3.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today ...

GlobeNewsWire - 1 month ago

AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- P lus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized th...

GlobeNewsWire - 1 month ago

AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today ...

GlobeNewsWire - 1 month ago

AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized ...

GlobeNewsWire - 2 months ago

Investigational drug RNL ™ d eliver s u p to fifteen t imes the a bsorbed d ose of r adiation c ompared to standard e xternal b eam r adiation t herapy

GlobeNewsWire - 2 months ago

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today ...

GlobeNewsWire - 2 months ago

Company Management and Principal Investigator of ReSPECT to Discuss Interim Data

GlobeNewsWire - 2 months ago

Data and Safety Monitoring Board evaluated safety data in recommending cohort progression Data and Safety Monitoring Board evaluated safety data in recommending cohort progression

Seeking Alpha - 3 months ago

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

– Receive d FDA O rphan D rug and Fast Track designations for novel glioblastoma radiotherapy –

GlobeNewsWire - 3 months ago

AUSTIN, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to participate in the Cancer Innovation Summit...

GlobeNewsWire - 3 months ago

AUSTIN, Texas, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today ...

GlobeNewsWire - 3 months ago

AUSTIN, Texas, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced the appointment of five leading experts in the fields of neurological s...

GlobeNewsWire - 3 months ago

Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™) Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (...

GlobeNewsWire - 4 months ago

AUSTIN, Texas, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted the C...

GlobeNewsWire - 4 months ago

AUSTIN, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it has been invited to present at the 22nd H. C. Wainwright ...

GlobeNewsWire - 4 months ago

AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it has been invited to present at the 9 th Annual Gateway...

Benzinga - 4 months ago

Plus Therapeutics (NASDAQ: PSTV) shares are trading higher Tuesday after the company announced the Food and Drug Administration has granted orphan drug designation for Rhenium NanoLiposomes fo...

GlobeNewsWire - 4 months ago

AUSTIN, Texas, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc (Exchange: PSTV) , today announced that it will be presenting at the LD 500 investor conference on Friday, September 4...

Seeking Alpha - 5 months ago

Plus Therapeutics, Inc.(PSTV) CEO Marc Hedrick on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced financial and business results for its Second Quarter Fiscal Year 2...

GlobeNewsWire - 5 months ago

AUSTIN, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it will report its Second Quarter Fiscal Year 2020 financial re...

GlobeNewsWire - 5 months ago

AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced the successful completion of the fifth cohort of the ReSPECT Clinica...

GlobeNewsWire - 6 months ago

AUSTIN, Texas, July 23, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced that it will be presenting at the YAFO ACCESS CHINA - 2020 Summer On...

GlobeNewsWire - 6 months ago

AUSTIN, Texas, July 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that the compensation committee of the Company’s board of directors approved an induce...

Seeking Alpha - 8 months ago

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

AUSTIN, Texas, May 14, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced financial and business results for its first quarter fiscal year 202...

GlobeNewsWire - 8 months ago

AUSTIN, Texas, May 11, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”, “Plus”), today announced the closing of its previously announced definitive agreement...

GlobeNewsWire - 9 months ago

AUSTIN, Texas, April 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it is donating personal protective equipment to San Diego’s S...

GlobeNewsWire - 9 months ago

AUSTIN, Texas, April 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Dr. Gregory Stein has joined the Company as Senior Vice Presi...

Seeking Alpha - 9 months ago

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2019 Results Conference Call March 30, 2020 5:00 PM ET

Benzinga - 9 months ago

Plus Therapeutics (NASDAQ: PSTV) shares are trading higher on Monday. The company announced it has entered into an agreement to license multiple rare cancer drug product candidates from NanoTx...

GlobeNewsWire - 10 months ago

Dr. Robert Lenk and Mr. Howard Clowes Dr. Robert Lenk and Mr. Howard Clowes

GlobeNewsWire - 11 months ago

AUSTIN, Texas, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Andrew J. Sims has been appointed as the company’s Chief Finan...

GlobeNewsWire - 11 months ago

AUSTIN, Texas, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Greg B. Petersen has joined the Company’s Board of Directors t...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today issued the following Letter to Shareholders from Dr. Marc Hedrick, President a...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Dr. An van Es-Johansson has joined the Company’s Board of Dire...

Seeking Alpha - 1 year ago

Plus Therapeutics, Inc. (PSTV) CEO Dr.

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it received a $4.6 million payment from the U.S. Department of ...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the closing of its previously announced underwritten public offering ...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the pricing of an underwritten public offering (the “Offering”) of 3,...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it received notice from the U.S. Department of Health and Huma...

Benzinga - 1 year ago

Plus Therapeutics Inc (NASDAQ: PSTV) is the latest and one of the most extreme recent examples of the powerful combination of low float and heavy trading volume.

About PSTV

Plus Therapeutics, a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develo... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Marc Hedrick
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
PSTV
Full Company Profile

Financial Performance

In 2019, PSTV's revenue was $7.00 million, an increase of 134.60% compared to the previous year's $2.98 million. Losses were -$10.89 million, -13.83% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for PSTV stock is "Buy." The 12-month stock price forecast is 5.63, which is an increase of 99.93% from the latest price.

Price Target
$5.63
(99.93% upside)
Analyst Consensus: Buy